 April 27, 2007
|
PIs During Pregnancy: Limited Glucose Problems
Protease inhibitors were not associated with increased glucose tolerance or insulin resistance in a study of HIV-positive women who received protease inhibitor-based antiretroviral therapy during pregnancy.
|
|
|
April 24, 2007
|
First CCR5 Blocker Gets Vote of Approval
An advisory committee to the FDA has voted unanimously to recommend the approval of Pfizer’s Celsentri® (maraviroc), an HIV entry inhibitor (EI) that targets the CCR5 receptor on CD4 cells.
|
|
|
April 19, 2007
|
Natural Molecule in Blood Blocks HIV
A new paper published in the journal Cell indicates that researchers have isolated yet another natural ingredient in human blood that effectively blocks the binding of HIV to CD4 cells.
|
|
|
April 13, 2007
|
571 on ADAP Waiting Lists
As of March 2007, four states have reported waiting lists for their ADAPs totaling 571 HIV-positive people in need, according to the 2007 National ADAP Monitoring Project Report.
|
|
|
April 12, 2007
|
AIDS Drugs Sales to Top $10 Billion by 2015
The launch of new drugs and an increase in the number of people diagnosed with HIV is set to make AIDS medicine a $10.6 billion market by 2015, according to a report on Thursday.
|
|
|
April 11, 2007
|
Pill Training for HIV+ Kids
Training to increase pill-swallowing skills has a number of potential beneficial effects in children with HIV/AIDS, researchers report in the April issue of Pediatrics.
|
|
|
Thailand and Abbott Spar Over Kaletra
Abbott Laboratories Inc., under fire for aggressive pricing of its AIDS medications in poor countries, said on Tuesday it would slash the price of its HIV protease inhibitor Kaletra (lopinavir + ritonavir) by more than half.
|
|
|
April 10, 2007
|
Home HIV Test in the Works
OraSure Technologies is looking to petition the U.S. Food and Drug Administration (FDA) to approve the assay for over-the-counter availability and home testing.
|
|
|
Rabies: An HIV Therapy?
New research suggests that the virus responsible for rabies may play a significant role in the development of a vaccine to help treat HIV.
|
|
|
April 09, 2007
|
Hepatitis A Endemic Among Gay Men in Europe
Molecular epidemiological studies indicate that, because of the interconnection between male homosexual communities in Europe, hepatitis A virus (HAV) is now endemic in this population.
|
|
|
April 06, 2007
|
48-Week Prezista Data Published
The Lancet has published final data from two key clinical trials of Prezista (darunavir), Tibotec’s new protease inhibitor, indicating that the drug offers prolonged treatment effects for HIV-positive people with limited treatment options.
|
|
|
April 05, 2007
|
Large Study Links Meth Use and HIV Risk
New study results have established methamphetamine use as an independent risk factor for HIV transmission and, when combined with other risk factors like unprotected receptive anal intercourse with multiple partners, the chances of seroconversion increases substantially.
|
|
|
April 04, 2007
|
Chemo Safe for Lung Cancer in High CD4 Pts
HIV-infected patients with CD4 cell counts above 200 who develop lung
cancer can withstand chemotherapy without a significant loss in
survival, according to a new study.
|
|
|
April 02, 2007
|
GSK Reports Combivir and Ziagen Tampering
Third-party tampering has resulted in misbranding of Ziagen® tablets as Combivir® tablets and employed counterfeit labels for Combivir tablets. GlaxoSmithKline is recommended that all Combivir and Ziagen users check their meds.
|
|
|
Hep C Treatment Cost Effective in Coinfected Patients
Hepatitis C (HCV) treatment is cost effective in patients coinfected with HIV, according to a report in the March issue of The American Journal of Medicine. Treatment also provides "substantial" benefits in life expectancy.
|
|
|
|
